These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 26953659

  • 1. Prognostic Role of Early and End-of-Neoadjuvant Treatment 18F-FDG PET/CT in Patients With Breast Cancer.
    García Vicente AM, Amo-Salas M, Relea Calatayud F, Muñoz Sánchez Mdel M, Pena Pardo FJ, Jiménez Londoño GA, Álvarez Cabellos R, Espinosa Aunión R, Soriano Castrejón Á.
    Clin Nucl Med; 2016 Jul; 41(7):e313-22. PubMed ID: 26953659
    [Abstract] [Full Text] [Related]

  • 2. Intratumoral heterogeneity in 18F-FDG PET/CT by textural analysis in breast cancer as a predictive and prognostic subrogate.
    Molina-García D, García-Vicente AM, Pérez-Beteta J, Amo-Salas M, Martínez-González A, Tello-Galán MJ, Soriano-Castrejón Á, Pérez-García VM.
    Ann Nucl Med; 2018 Jul; 32(6):379-388. PubMed ID: 29869770
    [Abstract] [Full Text] [Related]

  • 3. Early and delayed prediction of axillary lymph node neoadjuvant response by (18)F-FDG PET/CT in patients with locally advanced breast cancer.
    García Vicente AM, Soriano Castrejón Á, León Martín A, Relea Calatayud F, Muñoz Sánchez Mdel M, Cruz Mora MÁ, Jiménez Londoño GA, Espinosa Aunión R.
    Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1309-18. PubMed ID: 24744045
    [Abstract] [Full Text] [Related]

  • 4. Predictive and prognostic potential of volume-based metabolic variables obtained by a baseline 18F-FDG PET/CT in breast cancer with neoadjuvant chemotherapy indication.
    Garcia-Vicente AM, Pérez-Beteta J, Amo-Salas M, Molina D, Jimenez-Londoño GA, Soriano-Castrejón AM, Pena Pardo FJ, Martínez-González A.
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018 Jul; 37(2):73-79. PubMed ID: 29102649
    [Abstract] [Full Text] [Related]

  • 5. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J, Wang Y, Mo M, Bao X, Zhang Y, Liu G, Zhang J, Geng D.
    Oncotarget; 2015 Oct 06; 6(30):29388-95. PubMed ID: 26336821
    [Abstract] [Full Text] [Related]

  • 6. Staging of locally advanced breast cancer and the prediction of response to neoadjuvant chemotherapy: complementary role of scintimammography and 18F-FDG PET/CT.
    Evangelista L, Cervino AR, Michieletto S, Saibene T, Orvieto E, Bozza F, Ghiotto C.
    Q J Nucl Med Mol Imaging; 2017 Jun 06; 61(2):205-215. PubMed ID: 25501326
    [Abstract] [Full Text] [Related]

  • 7. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
    Koolen BB, Valdés Olmos RA, Wesseling J, Vogel WV, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Vrancken Peeters MJ.
    Ann Surg Oncol; 2013 Jul 06; 20(7):2227-35. PubMed ID: 23456316
    [Abstract] [Full Text] [Related]

  • 8. Glycolytic activity in breast cancer using 18F-FDG PET/CT as prognostic predictor: A molecular phenotype approach.
    Garcia Vicente AM, Soriano Castrejón A, Amo-Salas M, Lopez Fidalgo JF, Muñoz Sanchez MM, Alvarez Cabellos R, Espinosa Aunion R, Muñoz Madero V.
    Rev Esp Med Nucl Imagen Mol; 2016 Jul 06; 35(3):152-8. PubMed ID: 26522003
    [Abstract] [Full Text] [Related]

  • 9. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
    Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, Park IA, Noh DY, Chung JK, Bang YJ.
    Breast Cancer; 2013 Apr 06; 20(2):167-73. PubMed ID: 22311581
    [Abstract] [Full Text] [Related]

  • 10. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D, Sanna A, Majdoub M, de Cremoux P, Giacchetti S, Teixeira L, Espié M, Merlet P, de Roquancourt A, Visvikis D, Hatt M, Resche-Rigon M, Hindié E.
    J Nucl Med; 2015 Jun 06; 56(6):824-31. PubMed ID: 25883123
    [Abstract] [Full Text] [Related]

  • 11. Subtype-Guided 18 F-FDG PET/CT in Tailoring Axillary Surgery Among Patients with Node-Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: A Feasibility Study.
    Wu S, Wang Y, Li J, Zhang N, Mo M, Klimberg S, Kaklamani V, Cochet A, Shao Z, Cheng J, Liu G.
    Oncologist; 2020 Apr 06; 25(4):e626-e633. PubMed ID: 32297448
    [Abstract] [Full Text] [Related]

  • 12. Locoregional lymph node involvement on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy.
    Koolen BB, Valdés Olmos RA, Elkhuizen PH, Vogel WV, Vrancken Peeters MJ, Rodenhuis S, Rutgers EJ.
    Breast Cancer Res Treat; 2012 Aug 06; 135(1):231-40. PubMed ID: 22872522
    [Abstract] [Full Text] [Related]

  • 13. Complete Metabolic Response on Interim 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography to Predict Long-Term Survival in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy.
    Chen S, Ibrahim NK, Yan Y, Wong ST, Wang H, Wong FC.
    Oncologist; 2017 May 06; 22(5):526-534. PubMed ID: 28377466
    [Abstract] [Full Text] [Related]

  • 14. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT, Oksala N, Salo JA, Helin H, Karhumäki L, Kemppainen J, Sihvo EI, Räsänen JV.
    Acta Oncol; 2012 May 06; 51(5):636-44. PubMed ID: 22208782
    [Abstract] [Full Text] [Related]

  • 15. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Luo J, Zhou Z, Yang Z, Chen X, Cheng J, Shao Z, Guo X, Tuan J, Fu X, Yu X.
    Medicine (Baltimore); 2016 Feb 06; 95(8):e2914. PubMed ID: 26937935
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The role of FDG PET/CT in patients treated with neoadjuvant chemotherapy for localized bone sarcomas.
    Palmerini E, Colangeli M, Nanni C, Fanti S, Marchesi E, Paioli A, Picci P, Cambioli S, Donati D, Cevolani L, De Paolis M, Gambarotti M, Ferrari S.
    Eur J Nucl Med Mol Imaging; 2017 Feb 06; 44(2):215-223. PubMed ID: 27645694
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prognostic value of maximum standardized uptake value measured by pretreatment 18F-FDG PET/CT in locally advanced head and neck squamous cell carcinoma.
    Cacicedo J, Fernandez I, Del Hoyo O, Navarro A, Gomez-Iturriaga A, Pijoan JI, Martinez-Indart L, Escudero J, Gomez-Suarez J, de Zarate RO, Perez JF, Bilbao P, Rades D.
    Clin Transl Oncol; 2017 Nov 06; 19(11):1337-1349. PubMed ID: 28540535
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.